Logo

PDS Biotechnology Corporation

PDSB

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing… read more

Healthcare

Biotechnology

8 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$1.18

Price

-1.67%

-$0.02

Market Cap

$55.027m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$35.496m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$0.95

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$22.362m

$47.029m

Assets

$24.666m

Liabilities

$18.961m

Debt
Debt to Assets

40.3%

-0.5x

Debt to EBITDA
Free Cash Flow

-$34.153m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases